Amgen (AMGN) Bullish Stance Reiterated at Jefferies Following Repatha Panel Backing
Get Alerts AMGN Hot Sheet
Rating Summary:
20 Buy, 13 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Join SI Premium – FREE
Jefferies analyst Eun Yang reiterated a Buy rating and $195 price target on Amgen (NASDAQ: AMGN) after an FDA panel recommended approval of Repatha, as expected.
Yang commented, "Positive panel votes were widely expected (11-4 in favor for non-HoFH high-risk pts; 15-0 in favor for HoFH pts). AMGN notes pending CV outcomes data, panel outcome is in line. While no particular safety signals, given a large # of pts with hypercholesterolemia, panel would want to see CV outcomes data for a broader approval (FOURIER data <2017). For Repatha sales in 2016/2017, we modestly estimate ~$157M/$554M (~16K/54K pts on drug; vs. cons ~$426M/$869M)."
For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.
Shares of Amgen closed at $155.55 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
- Jefferies Downgrades Calix (CALX) to Hold
- RBB Bancorp (RBB) PT Raised to $22 at Keefe, Bruyette & Woods
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!